INCRUSE

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Lithuania, Netherlands, New Zealand, Poland, Singapore, Spain, Tunisia, UK.

Active ingredients

The drug INCRUSE contains one active pharmaceutical ingredient (API):

1	Umeclidinium UNII 7AN603V4JV - UMECLIDINIUM BROMIDE
	Umeclidinium is a long acting muscarinic receptor antagonist (also referred to as an anticholinergic). It is a quinuclidine derivative that is a muscarinic receptor antagonist with activity across multiple muscarinic cholinergic receptor subtypes. Umeclidinium bromide exerts its bronchodilatory activity by competitively inhibiting the binding of acetylcholine with muscarinic cholinergic receptors on airway smooth muscle.
	Read more about Umeclidinium

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
INCRUSE ELLIPTA Inhalation powder, pre-dispensed	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R03BB07		R Respiratory system → R03 Drugs for obstructive airway diseases → R03B Other drugs for obstructive airway diseases, inhalants → R03BB Anticholinergics
Discover more medicines within R03BB07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10187E
CA	Health Products and Food Branch	02423596
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	664-MEE-0115
EE	Ravimiamet	1646939, 1646940, 1646951
ES	Centro de información online de medicamentos de la AEMPS	114922002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	177512, 372536
FR	Base de données publique des médicaments	68964304
GB	Medicines & Healthcare Products Regulatory Agency	275680, 374397, 376667, 379895, 381406
HK	Department of Health Drug Office	63954
IE	Health Products Regulatory Authority	61510
IL	מִשְׂרַד הַבְּרִיאוּת	7556
LT	Valstybinė vaistų kontrolės tarnyba	1073276, 1073277, 1073278
NL	Z-Index G-Standaard, PRK	125318
NZ	Medicines and Medical Devices Safety Authority	17169
PL	Rejestru Produktów Leczniczych	100307439
SG	Health Sciences Authority	14853P
TN	Direction de la Pharmacie et du Médicament	2883041
US	FDA, National Drug Code	0173-0873